Acquired Hemophilia A - Hematology/Oncology Clinics
PharmaWiki - Emicizumab
Frontiers | Bispecific Antibodies: From Research to Clinical Application
Genentech: Hemlibra® (emicizumab-kxwh) - Information for Patients
NOVES LÍNIES DE FÀRMACS EN EL TRACTAMENT DE LA HEMOFILIA A
Emicizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
原创】血友病治疗在研项目深度解读系列之Emicizumab（一）：血友病治疗会迎来变革吗？_业界动态_新闻中心_苏州康宁杰瑞生物科技有限公司
Haemophilia - Wikipedia
Bispecific antibodies are progressing in cancer clinical trials
List of therapeutic monoclonal antibodies - Wikipedia
What is the mechanism of action of emicizumab? - Quora
Haemophilia - Wikipedia
Emicizumab Prophylaxis in Hemophilia A with Inhibitors | NEJM
Roche - Wikipedia
Emicizumab Prophylaxis in Hemophilia A with Inhibitors | NEJM
Emicizumab Prophylaxis in Hemophilia A with Inhibitors | NEJM
Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention - Research and Practice in Thrombosis and Haemostasis
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors - Escobar -
Arun KEEPANASSERIL | Research and Data Operations Lead, McMaster Hemophilia Resrarch Group | MDS,MSc,CPHIMS -CA | McMaster University, Hamilton | McMaster | Health Information Research Unit (HIRU) | Research profile
Haemophilia | Encyclopedia MDPI
Frontiers | Bispecific Antibodies: From Research to Clinical Application
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors | Science Translational Medicine
Haemophilia A & B – Blood & Water
Bispecific antibodies are progressing in cancer clinical trials
Importance of Early Active Engagement of Patients Throughout the Life Cycle of Drug Development
Digging into drug's effect on aPTT-based assays - CAP TODAY
